{"analyses":[{"ciLowerLimit":"1.05","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.97","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"1.77"},{"ciLowerLimit":"2.25","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.48","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","paramType":"Odds Ratio (OR)","paramValue":"3.82"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.7","upperLimit":"61.5","value":"52.1"},{"groupId":"OG001","lowerLimit":"61.3","upperLimit":"77.7","value":"70.0"},{"groupId":"OG002","lowerLimit":"29.1","upperLimit":"47.2","value":"37.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"130"},{"groupId":"OG002","value":"119"}],"units":"Participants"}],"description":"Comparison of percentage of patients with at least ≥ 25% reduction in seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. At least 25% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL","id":"OG000","title":"Everolimus LT Target of 3 to 7 ng/mL"},{"description":"Participants were randomized to receive everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL","id":"OG001","title":"Everolimus HT Target of 9 to 15 ng/mL"},{"description":"Participants were randomized to receive placebo dispersible tablets for oral suspension.","id":"OG002","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization","reportingStatus":"POSTED","timeFrame":"Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)","title":"Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}